BYSI logo

BEYONDSPRING INC

BYSINASDAQ
🏆 #4634 by market capUS Equity
$0.46▲ $0.01 (+3.30%)
Pre-market · at close
🔔
Track BYSI
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.3%
7d▼ 7.3%
14d▼ 26.5%
30d▼ 40.2%
ytd▼ 71.0%
1y▼ 74.8%
🏦Market Cap
$19M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.46 – $0.46
52-Week Range
$0.42 – $2.44
Volume (shares)
106
Avg Volume (shares)
—
Shares Outstanding
41.1M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-2.8
P/S Ratio
0.0x
EPS (TTM)
$-0.16
Dividend Yield
0.00%
Dilution (1yr)
+1.7%
BYSI logo

BEYONDSPRING INC

BYSI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▲ +2.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$20M▲ +20.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
40.4M▲ +1.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▲ +$5M YoY
StockOtter · stockotter.space

About BEYONDSPRING INC

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.